FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics shares are plummeting after FDA staff disputed the company's claims of Phase 3 success for its DMD cell therapy.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
FDA documents have raised concerns regarding the data for Capricor's therapy, deramiocel, leading to a sharp decline in CAPR stock. BioSpace reports that the FDA disputes the company's assertions of success in Phase 3 trials for the Duchenne muscular dystrophy (DMD) treatment.
Coverage from Yahoo Finance highlights a divide among analysts regarding the probability of the therapy's approval. Simultaneously, legal firms including Kehoe Law Firm, P.C. and Holzer & Holzer, LLC have announced investigations into Capricor Therapeutics following the news.
Attention now turns to August 2026, the timeframe identified by RTTNews for the FDA's decision on biotech stocks including this therapy.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated just now.
Quick answers
What specific therapy is causing the controversy?
The therapy is deramiocel, a cell therapy intended for DMD.
How has the market responded to the FDA documents?
According to Yahoo Finance, CAPR stock is on track for its worst day ever.
When is the FDA's decision expected?
Coverage indicates a decision is expected in August 2026.
Coverage (5)
- CAPR Investor Alert: Kehoe Law Firm, P.C. Investigates Capricor T The National Law Review · 8h ago
- CAPR Stock On Track For Worst Day Ever — Analysts Divided On Deramiocel’s Approval Probability After FDA Documents Paint ‘Ugly Picture’ Yahoo Finance · 8h ago
- Biotech Stocks Facing FDA Decision In August 2026 RTTNews · 8h ago
- CAPR INVESTOR ALERT: Investigation of Capricor Therapeutics, Inc. Announced by Holzer & Holzer, LLC GlobeNewswire · 8h ago
- FDA disputes Capricor’s claims of Phase 3 success for DMD cell therapy BioSpace · 8h ago broke it first
People, places & organizations
Topics
Related trends
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics shares declined following the release of mixed Phase 2 trial results for its schizophrenia drug candidate.
The FDA Issued a Recall on Thyroid Medication Nationwide
The FDA has issued a nationwide recall of levothyroxine sodium tablets due to the drug being described as subpotent.
Argenx to Buy Forte Biosciences for $2.2 Billion
Argenx is expanding its immunology pipeline through a $2.2 billion acquisition of autoimmune biotech company Forte Biosciences.
Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug
Capricor Therapeutics shares have plunged after FDA staff raised concerns regarding the efficacy and data of its Duchenne heart disease therapy.
Compounded GLP-1 drugs creating concern among doctors and FDA
Doctors and the FDA are warning against the use of compounded GLP-1 weight-loss drugs due to potential health risks and troubling study findings.
FDA Approves Centanafadine for ADHD in Children, Adolescents, and Adults
The FDA has approved Simtriyo (centanafadine), the first new-class ADHD medication for children and adults in decades.